Rockefeller Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Sell |
216,765
-170,691
| -44% | -$864K | ﹤0.01% | 1287 |
|
|
2025
Q1 | $2.05M | Buy |
387,456
+105,534
| +37% | +$558K | 0.01% | 1033 |
|
|
2024
Q4 | $1.91M | Buy |
281,922
+215,283
| +323% | +$1.46M | ﹤0.01% | 1028 |
|
|
2024
Q3 | $439K | Buy |
+66,639
| New | +$439K | ﹤0.01% | 1465 |
|
|
2024
Q2 | – | Sell |
-21,246
| Closed | -$212K | – | 1721 |
|
|
2024
Q1 | $212K | Buy |
+21,246
| New | +$212K | ﹤0.01% | 1653 |
|
|
2023
Q1 | – | Sell |
-2,378
| Closed | -$18K | – | 3536 |
|
|
2022
Q4 | $18K | Sell |
2,378
-4,941
| -68% | -$37.4K | ﹤0.01% | 2849 |
|
|
2022
Q3 | $77K | Buy |
7,319
+1,378
| +23% | +$14.5K | ﹤0.01% | 2136 |
|
|
2022
Q2 | $48K | Sell |
5,941
-6,647
| -53% | -$53.7K | ﹤0.01% | 2315 |
|
|
2022
Q1 | $90K | Buy |
12,588
+2,191
| +21% | +$15.7K | ﹤0.01% | 2031 |
|
|
2021
Q4 | $178K | Buy |
10,397
+8,347
| +407% | +$143K | ﹤0.01% | 1691 |
|
|
2021
Q3 | $47K | Buy |
2,050
+1,050
| +105% | +$24.1K | ﹤0.01% | 2171 |
|
|
2021
Q2 | $36K | Buy |
+1,000
| New | +$36K | ﹤0.01% | 2232 |
|